A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
TCR2 Therapeutics
Artiva Biotherapeutics, Inc.
GC Cell Corporation
Acepodia Biotech, Inc.
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics